Inspire Medical Systems, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Inspire Medical Systems, Inc. announces robust 2025 financial and operational growth, including $912 million in revenue and over 125,000 patients treated, alongside proposals for board declassification and an equity plan amendment.
NYSE
Inspire Medical Systems, Inc. has filed a definitive proxy statement with the SEC.
NYSE
Inspire Medical Systems announces a profitable 2024, FDA approval for its Inspire V system, and changes to its Board and executive management.
NYSE
Inspire Medical Systems, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NYSE
Inspire Medical Systems' proxy statement details the agenda for the 2024 annual meeting, including director elections, auditor ratification, executive compensation approval, and board leadership transition.